Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GTAC (Gene Therapy Advisory Committee) reports state of UK gene therapy R&D (research and development):

This article was originally published in Clinica

Executive Summary

The year 2000 saw a three-fold increase in the number of UK-based gene therapy trials, of which some are beginning to show "exciting results", says the UK's Gene Therapy Advisory Committee (GTAC) in its annual report for 2000. Over 400 patients have taken part in the 72 gene therapy trials conducted since 1992. Early results suggest a high degree of success in some of these studies, including severe combined immunodeficiency (SCID), melanoma, brain tumours, prostate cancer and lymphoma. The report also includes details of all the proposals reviewed by GTAC in 2000. GTAC assesses the ethical acceptability of proposals for gene therapy research on humans, taking into account the scientific merits and potential benefits and risks to patients. It also advises government on developments in this field.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074475

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel